Focus:
Cardiovascular
-
15 January 2020 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
13 January 2020 News
AZ to take $100m hit from ending trial of CV drug Epanova
AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3 carboxylic acids) following a recommendation by an Independent Data Monitory Committee that the drug was...
-
8 January 2020 Analysis
No more siloes: linking rheumatology and CVD with Abcentra
Although there are evidence-based links between CVD and inflammatory conditions, and associated strong risk factors, they are often ignored when treating patients with either type of condition. Abcentra former CEO...
-
6 January 2020 News
AstraZeneca secures FDA priority review for Farxiga
AstraZeneca has secured the US Food and Drug Administration (FDA) priority review for Farxiga (dapagliflozin) to treat heart failure with reduced ejection fraction (HFrEF).
-
3 January 2020 Analysis
2019 top news stories
BMS acquires Celgene for an equity value of $74bn and GSK signs $4.2bn immunotherapy deal with the Merck group. Pharmaceutical-technology.com wraps up key headlines from 2019.
-
17 December 2019 News
NICE recommends Vifor’s Veltassa for routine NHS use
Vifor Pharma has announced that the National Institute for Health and Care Excellence (NICE) has recommended Veltassa (patiromer) for routine use through the National Health Service (NHS).
-
16 December 2019 News
FDA approves Amarin’s Vascepa to reduce CV risk in heavily treated patients
The US Food and Drug Administration (FDA) has approved a label expansion for Amarin’s Vascepa (icosapent ethyl) based on its efficacy in reducing the risk of cardiovascular (CV) events in...
-
16 December 2019 News
Pfizer receives CHMP recommendation for rare cardiomyopathy drug
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the authorisation of Pfizer’s Vyndaqel (tafamidis) for a rare type of cardiomyopathy.
-
13 December 2019 Comment
Does regular brushing of teeth reduce the risk of heart failure?
Although the mechanism is unclear, it has been suggested that frequent brushing removed harmful bacteria from the mouth, thus preventing translocation in the bloodstream.
-
10 December 2019 Analysis
Twitter round-up: Cardiovascular trends in November 2019
Pharmaceutical Technology lists ten of the most popular tweets in cardiovascular in November 2019, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked...